HRP20211670T1 - Derivat difenilmetana u kristalnom obliku - Google Patents
Derivat difenilmetana u kristalnom obliku Download PDFInfo
- Publication number
- HRP20211670T1 HRP20211670T1 HRP20211670TT HRP20211670T HRP20211670T1 HR P20211670 T1 HRP20211670 T1 HR P20211670T1 HR P20211670T T HRP20211670T T HR P20211670TT HR P20211670 T HRP20211670 T HR P20211670T HR P20211670 T1 HRP20211670 T1 HR P20211670T1
- Authority
- HR
- Croatia
- Prior art keywords
- crystalline form
- xrd
- irradiation
- spectrum
- light source
- Prior art date
Links
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 title 1
- 238000002441 X-ray diffraction Methods 0.000 claims 4
- 238000001228 spectrum Methods 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B51/00—Introduction of protecting groups or activating groups, not provided for in the preceding groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (1)
1. Kristalni oblik spoja sljedeće Formule c28.
[image]
pri čemu kristalni oblik ima spektar difrakcije rendgenskih zraka (XRD) koji uključuje vrhove pod kutovima difrakcije (2θ) od 6.2°±0.2°, 7.2°±0.2°, 8.8°±0.2°, 17.6°±0.2°, 19.0°±0.2°, 22.5°±0.2°, i 25.1°±0.2° u slučaju zračenja pomoću Cu-Kα izvora svjetlosti; ili
pri čemu kristalni oblik ima spektar difrakcije rendgenskih zraka (XRD) koji uključuje vrhove pod kutovima difrakcije (2θ) od 7.0°±0.2°, 14.9°±0.2°, 17.7°±0.2°, 18.8°±0.2°, 20.6°±0.2°, 21.8°±0.2°, i 23.5°±0.2° u slučaju zračenja pomoću Cu-Kα izvora svjetlosti; ili
pri čemu kristalni oblik ima spektar difrakcije rendgenskih zraka (XRD) koji uključuje vrhove pod kutovima difrakcije (2θ) od 5.6°±0.2°, 7.3°±0.2°, 15.7°±0.2°, 17.2°±0.2°, 18.9°±0.2°, 21.2°±0.2°, i 21.9°±0.2° u slučaju zračenja pomoću Cu-Kα izvora svjetlosti; ili
pri čemu kristalni oblik ima spektar difrakcije rendgenskih zraka (XRD) koji uključuje vrhove pod kutovima difrakcije (2θ) od 5.5°±0.2°, 7.2°±0.2°, 15.3°±0.2°, 17.2°±0.2°, 17.6°±0.2°, 18.9°±0.2°, i 21.1°±0.2° u slučaju zračenja pomoću Cu-Kα izvora svjetlosti.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160075910 | 2016-06-17 | ||
EP20152959.1A EP3663292B1 (en) | 2016-06-17 | 2017-06-15 | Diphenylmethane derivative in crystalline form |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20211670T1 true HRP20211670T1 (hr) | 2022-02-18 |
HRP20211670T8 HRP20211670T8 (hr) | 2022-03-18 |
Family
ID=60664449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211670TT HRP20211670T8 (hr) | 2016-06-17 | 2017-06-15 | Derivat difenilmetana u kristalnom obliku |
Country Status (30)
Country | Link |
---|---|
US (2) | US10640496B2 (hr) |
EP (2) | EP3473621B1 (hr) |
JP (4) | JP6763978B2 (hr) |
KR (2) | KR102233229B1 (hr) |
CN (2) | CN113651803B (hr) |
AU (1) | AU2017285813B2 (hr) |
BR (1) | BR112018076243A2 (hr) |
CA (2) | CA3026756C (hr) |
CL (1) | CL2018003645A1 (hr) |
CO (1) | CO2018014018A2 (hr) |
DK (2) | DK3663292T3 (hr) |
DO (1) | DOP2018000287A (hr) |
EC (1) | ECSP19000185A (hr) |
ES (2) | ES2898336T3 (hr) |
HR (1) | HRP20211670T8 (hr) |
HU (1) | HUE056428T2 (hr) |
MA (2) | MA44545B2 (hr) |
MX (2) | MX2021008988A (hr) |
MY (1) | MY203941A (hr) |
NZ (1) | NZ749398A (hr) |
PE (2) | PE20240590A1 (hr) |
PH (1) | PH12018550206A1 (hr) |
PL (2) | PL3473621T3 (hr) |
PT (2) | PT3473621T (hr) |
RS (1) | RS62550B1 (hr) |
SA (2) | SA518400666B1 (hr) |
SG (2) | SG11201811154QA (hr) |
SI (1) | SI3663292T1 (hr) |
TN (1) | TN2018000437A1 (hr) |
WO (1) | WO2017217792A1 (hr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011054773A1 (de) | 2011-10-25 | 2013-04-25 | Vb Autobatterie Gmbh & Co. Kgaa | Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols |
KR102307475B1 (ko) * | 2018-08-13 | 2021-09-30 | 주식회사 대웅제약 | Sglt 저해제의 합성에 유용한 중간체의 제조 |
CN112341416A (zh) * | 2019-08-09 | 2021-02-09 | 天津津艺医药科技发展有限责任公司 | 一种制备苯并含氧脂杂环衍生物的方法 |
AU2021225706B2 (en) * | 2020-02-27 | 2024-06-13 | Daewoong Pharmaceutical Co., Ltd. | Intermediate useful for synthesis of SGLT inhibitor and method for preparing SGLT inhibitor using same |
CN112094253B (zh) * | 2020-09-10 | 2023-01-10 | 株式会社大熊制药 | 用于制备sglt抑制剂中间体的合成方法 |
CA3191689A1 (en) | 2020-09-10 | 2022-03-17 | Zhining HUANG | Synthesis method for preparing sglt inhibitor intermediate |
CN113200860B (zh) * | 2021-04-29 | 2024-07-30 | 爱斯特(成都)生物制药股份有限公司 | 一种sglt2抑制剂中间体的制备方法 |
CN113801010A (zh) * | 2021-11-18 | 2021-12-17 | 山东诚创蓝海医药科技有限公司 | 一种5-溴-2-氯苯甲酸的制备方法 |
CN113912487B (zh) * | 2021-11-23 | 2024-05-28 | 山东研峰新材料科技有限公司 | 一种2,5-双卤代苯甲酸的合成方法 |
KR20230110001A (ko) | 2022-01-14 | 2023-07-21 | 주식회사 대웅제약 | Ssglt 저해제의 합성에 유용한 중간체의 제조 방법 |
KR20240044194A (ko) | 2022-09-28 | 2024-04-04 | 주식회사 대웅제약 | 이나보글리플로진의 신규한 공결정 |
KR20240044190A (ko) * | 2022-09-28 | 2024-04-04 | 주식회사 대웅제약 | 이나보글리플로진의 신규한 결정형 및 이의 제조방법 |
WO2024136385A1 (ko) | 2022-12-21 | 2024-06-27 | 주식회사 대웅테라퓨틱스 | 이나보글리플로진을 포함하는 점안제 형태의 약학 조성물 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4966907A (en) * | 1988-08-12 | 1990-10-30 | Merck & Co., Inc. | 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis |
EA010299B1 (ru) * | 2003-08-01 | 2008-08-29 | Мицубиси Танабе Фарма Корпорейшн | Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортёра |
NZ582536A (en) | 2007-07-26 | 2012-01-12 | Lexicon Pharmaceuticals Inc | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
TW201018695A (en) | 2008-07-30 | 2010-05-16 | Ferrer Int | 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds |
US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
WO2012041898A1 (en) * | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes |
KR101576589B1 (ko) | 2011-06-01 | 2015-12-10 | 주식회사 녹십자 | Sglt2 억제제로서의 신규한 다이페닐메탄 유도체 |
US9340521B2 (en) | 2013-03-18 | 2016-05-17 | Green Cross Corporation | Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives |
FR3017868A1 (fr) | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2017
- 2017-06-15 AU AU2017285813A patent/AU2017285813B2/en active Active
- 2017-06-15 MX MX2021008988A patent/MX2021008988A/es unknown
- 2017-06-15 EP EP17813615.6A patent/EP3473621B1/en active Active
- 2017-06-15 WO PCT/KR2017/006271 patent/WO2017217792A1/ko active Application Filing
- 2017-06-15 BR BR112018076243-1A patent/BR112018076243A2/pt active Search and Examination
- 2017-06-15 ES ES20152959T patent/ES2898336T3/es active Active
- 2017-06-15 PL PL17813615T patent/PL3473621T3/pl unknown
- 2017-06-15 CN CN202110860586.9A patent/CN113651803B/zh active Active
- 2017-06-15 ES ES17813615T patent/ES2891825T3/es active Active
- 2017-06-15 CA CA3026756A patent/CA3026756C/en active Active
- 2017-06-15 SI SI201730944T patent/SI3663292T1/sl unknown
- 2017-06-15 PE PE2023002240A patent/PE20240590A1/es unknown
- 2017-06-15 MA MA44545A patent/MA44545B2/fr unknown
- 2017-06-15 EP EP20152959.1A patent/EP3663292B1/en active Active
- 2017-06-15 MY MYPI2018002498A patent/MY203941A/en unknown
- 2017-06-15 PT PT17813615T patent/PT3473621T/pt unknown
- 2017-06-15 TN TNP/2018/000437A patent/TN2018000437A1/en unknown
- 2017-06-15 SG SG11201811154QA patent/SG11201811154QA/en unknown
- 2017-06-15 DK DK20152959.1T patent/DK3663292T3/da active
- 2017-06-15 MA MA50774A patent/MA50774B1/fr unknown
- 2017-06-15 HU HUE20152959A patent/HUE056428T2/hu unknown
- 2017-06-15 CN CN201780036968.1A patent/CN109311861B/zh active Active
- 2017-06-15 HR HRP20211670TT patent/HRP20211670T8/hr unknown
- 2017-06-15 DK DK17813615.6T patent/DK3473621T3/da active
- 2017-06-15 KR KR1020170075799A patent/KR102233229B1/ko active Protection Beyond IP Right Term
- 2017-06-15 SG SG10201911782RA patent/SG10201911782RA/en unknown
- 2017-06-15 PL PL20152959T patent/PL3663292T3/pl unknown
- 2017-06-15 CA CA3081033A patent/CA3081033C/en active Active
- 2017-06-15 NZ NZ749398A patent/NZ749398A/en unknown
- 2017-06-15 US US16/310,005 patent/US10640496B2/en active Active
- 2017-06-15 RS RS20211297A patent/RS62550B1/sr unknown
- 2017-06-15 MX MX2018015647A patent/MX2018015647A/es unknown
- 2017-06-15 PE PE2018003162A patent/PE20190467A1/es unknown
- 2017-06-15 PT PT201529591T patent/PT3663292T/pt unknown
- 2017-06-15 JP JP2018565754A patent/JP6763978B2/ja active Active
-
2018
- 2018-12-15 SA SA518400666A patent/SA518400666B1/ar unknown
- 2018-12-15 SA SA521422474A patent/SA521422474B1/ar unknown
- 2018-12-17 PH PH12018550206A patent/PH12018550206A1/en unknown
- 2018-12-17 DO DO2018000287A patent/DOP2018000287A/es unknown
- 2018-12-17 CL CL2018003645A patent/CL2018003645A1/es unknown
- 2018-12-21 CO CONC2018/0014018A patent/CO2018014018A2/es unknown
-
2019
- 2019-01-04 EC ECSENADI2019185A patent/ECSP19000185A/es unknown
- 2019-08-30 US US16/557,180 patent/US10889574B2/en active Active
-
2020
- 2020-04-06 JP JP2020068458A patent/JP7352509B2/ja active Active
-
2021
- 2021-03-22 KR KR1020210036824A patent/KR102379584B1/ko active IP Right Grant
- 2021-06-21 JP JP2021102648A patent/JP2021152054A/ja active Pending
-
2023
- 2023-07-06 JP JP2023111632A patent/JP2023145481A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211670T1 (hr) | Derivat difenilmetana u kristalnom obliku | |
HRP20210748T1 (hr) | Postupak priprave spojeva s aktivnošću inhibitora hiv integraze | |
PE20141061A1 (es) | Compuesto inhibidor de la senalizacion de la trayectoria notch | |
WO2014136282A8 (en) | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient | |
WO2017100726A8 (en) | Methods for treating huntington's disease | |
JP2019510768A5 (hr) | ||
CY1120173T1 (el) | Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης | |
EP3533794A3 (de) | Materialien für elektronische vorrichtungen | |
UY31419A1 (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen | |
RS52375B (en) | STABLE CRYSTALS OF 4-OXOCHINOLINE COMPOUND | |
HRP20170540T1 (hr) | Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja | |
FI3977993T3 (fi) | 6-karboksi-2-(3,5-dikloorifenyyli)bentsoksatsolin kiteiset kiinteät muodot käytettäväksi lääkkeenä | |
AR074507A1 (es) | Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra. | |
AR103444A1 (es) | Forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos | |
MY189352A (en) | Crystals of Azabicyclic Compound | |
WO2018151479A3 (ko) | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 | |
WO2015000431A9 (zh) | 替唑尼特氨基甲酸酯及其在药学中的应用 | |
AR075418A1 (es) | Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad. | |
WO2018004315A3 (ko) | 화합물 및 이를 포함하는 유기 전자 소자 | |
WO2015017378A3 (en) | Novel copper-cysteamine and methods of use | |
ES2650604T3 (es) | Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene | |
JP2015506941A5 (hr) | ||
MX2023004668A (es) | Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico. | |
EA202092393A1 (ru) | Кристаллическое соединение оксазола | |
CY1121811T1 (el) | Κρυσταλλικες μορφες s-ακετυλ γλουταθειονης, παρασκευη αυτων και χρησεις σε φαρμακευτικα και τροφιμοφαρμακευτικα σκευασματα |